How should upadacitinib be used, dosed, and monitored in adults with chronic spontaneous urticaria who have failed high‑dose second‑generation H1 antihistamines and are unsuitable for omalizumab?

Upadacitinib is NOT recommended for chronic spontaneous urticaria

Upadacitinib has no established role in the treatment of chronic spontaneous urticaria and does not appear in current international guidelines or FDA-approved indications for this condition. The evidence-based treatment algorithm for antihistamine-refractory CSU follows a clear stepwise approach that does not include JAK inhibitors like upadacitinib.

Current Guideline-Directed Treatment Algorithm

The 2022 international urticaria guidelines 1 establish a streamlined 3-step approach:

Step 1: Second-Generation H1-Antihistamines

• Start with standard-dose second-generation H1-antihistamines
• If inadequate control after 2-4 weeks, uptitrate to 4-fold the standard dose
• Continue high-dose antihistamines as background therapy throughout treatment

Step 2: Add Omalizumab (FDA-Approved for CSU)

For patients unsuitable for omalizumab or who have failed antihistamines:

The FDA-approved indication for omalizumab in CSU 2 specifies:

• Dosing: 150 mg or 300 mg subcutaneously every 4 weeks
• Key distinction: Unlike asthma or food allergy, CSU dosing is NOT dependent on serum IgE level or body weight
• Standard approach: Start with 300 mg every 4 weeks based on robust placebo-controlled trials 1
• Uptitration if needed: Can increase to 600 mg every 2 weeks for partial responders
• Duration: Allow up to 6 months for response assessment

Step 3: Cyclosporine

If omalizumab fails at optimized doses 1:

• Dose: Up to 5 mg/kg body weight
• Monitoring requirements: Blood pressure and renal function (BUN, creatinine) every 6 weeks
• Risks: Hypertension, renal impairment, hirsutism, gingival hypertrophy

Why Omalizumab Remains First Choice

The guideline explicitly states that "the risk-benefit profile of high-dose omalizumab is superior to that of cyclosporine" 1. Real-world data confirms 84% complete response rates with omalizumab in antihistamine-refractory CSU 3, with most responders achieving control after 1-2 doses.

Emerging Alternatives (Not Yet Guideline-Recommended)

Recent research 4, 5 identifies newer targeted therapies under investigation:

• Dupilumab (IL-4Rα antagonist) - approved 2025
• Remibrutinib (BTK inhibitor) - approved 2025
• Barzolvolimab (anti-KIT antibody) - phase 3 trials

However, these remain investigational or newly approved without established positioning relative to omalizumab.

Critical Clinical Pitfalls

1. Misdiagnosis: Ensure true CSU diagnosis (wheals lasting <24 hours, no identifiable trigger) before escalating therapy
2. Pseudo-resistance: Rule out poor adherence or incorrect antihistamine dosing before declaring treatment failure
3. Premature switching: Allow adequate trial duration - up to 6 months for omalizumab 1
4. Biomarker misuse: Do not retest IgE during omalizumab treatment; levels remain elevated up to 1 year post-discontinuation 2

If Patient is Truly Unsuitable for Omalizumab

Proceed directly to cyclosporine as the only guideline-endorsed third-line option 1. Consider enrollment in clinical trials for emerging biologics if cyclosporine is contraindicated or fails.

Bottom line: Upadacitinib has no evidence base or regulatory approval for CSU. Stick to the proven algorithm: optimize antihistamines → omalizumab (with uptitration if needed) → cyclosporine, with appropriate monitoring at each step.